Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Ellen A, Cannady"'
Autor:
Guoqing Cao, Thomas P. Beyer, Youyan Zhang, Robert J. Schmidt, Yan Q. Chen, Sandra L. Cockerham, Karen M. Zimmerman, Sotirios K. Karathanasis, Ellen A. Cannady, Todd Fields, Nathan B. Mantlo
Publikováno v:
Journal of Lipid Research, Vol 52, Iss 12, Pp 2169-2176 (2011)
Cholesteryl ester transfer protein (CETP) catalyses the exchange of cholesteryl ester and triglyceride between HDL and apoB containing lipoprotein particles. The role of CETP in modulating plasma HDL cholesterol levels in humans is well established a
Externí odkaz:
https://doaj.org/article/814d7db5161b4c7e8b11650ddcf3aa93
Autor:
Ming-Dauh Wang, Yimin Cui, David S. Small, Jian Jun Jin, Yan Liang, Jeffrey G. Suico, Ping Xin, Ellen A. Cannady, Xia Zhao
Publikováno v:
International Journal of Pharmacokinetics. 3:69-80
Aim: Evaluate steady-state pharmacokinetics and potential interactions between select statins and evacetrapib. Patients & methods: This open-label, two-part study included 62 healthy native Chinese subjects. Part 1 evaluated pharmacokinetics and phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f44977484031daa2a6ed1a865153aad
https://doi.org/10.4155/ipk-2017-0017
https://doi.org/10.4155/ipk-2017-0017
Autor:
Lew Truex, Jay K. Herman, John Morris Sullivan, Kanchan Narwani, Ellen A. Cannady, Thomas Ryan, Mark A. Carfagna
Publikováno v:
Regulatory Toxicology and Pharmacology. 92:458-471
Baricitinib is a potent and selective Janus kinase (JAK)1 and JAK2 inhibitor, and is approved for the treatment of moderately to severely active RA in adults in Europe, Japan, and other countries. This study evaluated the carcinogenic potential of ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82eb9c2e0ff18d96311a2b53fa68b1a1
https://doi.org/10.1016/j.yrtph.2017.11.020
https://doi.org/10.1016/j.yrtph.2017.11.020
Autor:
Maria M. Posada, Christopher D. Payne, Xin Zhang, Stephen D. Hall, J. William Higgins, Ellen A. Cannady, Y. Anne Pak, Nazila Shahri, Kathleen M. Hillgren, James A. Bacon
Publikováno v:
Clinical and Translational Science
Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, undergoes active renal tubular secretion. Baricitinib was not predicted to inhibit hepatic and renal uptake and efflux drug transporters, based on the ratio of the unbound maximum elimina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67824fb1c8fc327d01bf4f52cfc752f1
https://doi.org/10.1111/cts.12486
https://doi.org/10.1111/cts.12486
Publikováno v:
Birth Defects Research. 109:486-496
BACKGROUND Evacetrapib, a potent and selective inhibitor of cholesteryl ester transfer protein (CETP), was under development for the treatment of cardiovascular (CV) disease. The purpose of this pre-postnatal study in rabbits was to evaluate the effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3f4a2dff536b10273cc36adf1a85c68
https://doi.org/10.1002/bdr2.1017
https://doi.org/10.1002/bdr2.1017
Publikováno v:
Birth Defects Research. 109:513-527
Background The purpose of these studies was to evaluate the effects of evacetrapib on male and female fertility and on embryo-fetal development (EFD). Methods Evacetrapib, a potent and selective inhibitor of cholesteryl ester transfer protein (CETP),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c209ecb115bb4528de36b8e82949f24d
https://doi.org/10.1002/bdr2.1022
https://doi.org/10.1002/bdr2.1022
Autor:
Demetrio Ortega, Wei Zhang, David S. Small, Jeffrey G. Suico, Jane Royalty, Ellen A. Cannady, Delyn Downs
Publikováno v:
European Journal of Clinical Pharmacology
Purpose The aim of this study is to investigate the effect of hepatic or renal impairment on the pharmacokinetics of a single 130-mg evacetrapib dose. Methods Two open-label, parallel-design studies in males and females with normal hepatic function o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1194b09dc1d9926760e89ed5d5100b80
https://doi.org/10.1007/s00228-016-2017-1
https://doi.org/10.1007/s00228-016-2017-1
Autor:
Boris A. Czeskis, Demetrio Ortega, Brian W. Pack, Aktham Aburub, Chris Ward, David S. Small, Ellen A. Cannady, Syeda L. Begum, William F. Annes, Jane Royalty, Qun Lin, Kenneth J. Ruterbories, Chris Hinds, Jeffrey G. Suico
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 59:238-244
This open-label, single-period study in healthy subjects estimated evacetrapib absolute bioavailability following simultaneous administration of a 130-mg evacetrapib oral dose and 4-h intravenous (IV) infusion of 175 µg [(13) C8 ]-evacetrapib as a t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4beba73882159abdad3afbae34cd3e4d
https://doi.org/10.1002/jlcr.3358
https://doi.org/10.1002/jlcr.3358
Autor:
Amy L. Cox, Eyas Raddad, Timothy M. Jones, Charles Reidy, Michaël Genin, John R. Stille, Chahrzad Montrose-Rafizadeh, Wayne P. Bocchinfuso, Laura F. Michael, Ellen A. Cannady, Manninen Peter Rudolph, M. Dodson Michael, Javier Agejas Francisco, Ana B. Bueno
Publikováno v:
Journal of Medicinal Chemistry. 58:9768-9772
The farnesoid X receptor (FXR) is a member of the "metabolic" subfamily of nuclear receptors. Several FXR agonists have been reported in the literature to have profound effects on plasma lipids in animal models. To discover novel and effective therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae5fdc8964a35fa86c008ce8c81d6458
https://doi.org/10.1021/acs.jmedchem.5b01161
https://doi.org/10.1021/acs.jmedchem.5b01161
Autor:
Ming Dauh Wang, Stephen J. Nicholls, Ellen A. Cannady, Stuart Friedrich, Jessica Rehmel, Jeffrey G. Suico, Kathryn A. Krueger
Publikováno v:
British Journal of Clinical Pharmacology
Aims Evacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor under development for reducing cardiovascular events in patients with high risk vascular disease. CETP inhibitors are likely to be utilized as ‘add-on’ therapy to statins i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5dda0ae8262820a61d7f382c8550169
http://europepmc.org/articles/PMC4693478
http://europepmc.org/articles/PMC4693478